Vet­er­an amy­loid cham­pi­on helps Alzheimer's start­up grab $160M in IPO as in­vestors charge back in to a once fad­ed field

The amy­loid be­ta the­o­ry in Alzheimer’s re­search has staged a come­back with in­vestors as well as the FDA.

Thurs­day morn­ing Acu­men Phar­ma­ceu­ti­cals priced its up­sized IPO at $16, hit­ting the high end of the range and scor­ing $160 mil­lion for the biotech.

Acu­men pitched in­vestors on the idea that the biotech of­fers a dif­fer­en­ti­at­ed ap­proach to amy­loid, tar­get­ing sol­u­ble amy­loid-be­ta oligomers, or AbOs, with its lead can­di­date ACU193.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.